According to the research report, the global formulation development outsourcing market size is expected to touch USD 75.8 Billion by 2032, from USD 37.4 Billion in 2022, growing with a significant CAGR of 7.32% from 2023 to 2032. 

Key Takeaways:

• By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
• By service, the formulation development generated over 77% of revenue share in 2022.
• By formulation, the oral segment had the largest market share of 64% in 2022.
• By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
• By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.

The report offers intricate dynamics about different aspects of the global formulation development outsourcing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global formulation development outsourcing during the Forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/3192

This study covers a detailed segmentation of the global formulation development outsourcing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global formulation development outsourcing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• SGS S.A.
• Eurofins Scientific SE
• Element
• Labcorp
• Thermo Fisher Scientific, Inc. (Patheon)
• Intertek Group plc
• Recipharm
• Lonza
• Charles River Laboratories International, Inc.
• Catalent Inc.

Market Segmentation

By Service

• Preformulation
• Formulation Development

By Formulation

• Topical
• Oral
• Injectable
• Others

By Therapeutic Area

• Oncology
• Infectious Disease
• Respiratory
• Cardiovascular
• Neurology
• Hematology
• Dermatology
• Others

By End-User

• Pharmaceutical Industries
• Research and Academic Institutions

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Research Methodology

The research methodology adopted by analysts for compiling the global formulation development outsourcing report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global formulation development outsourcing market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market 

5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Formulation Development Outsourcing Market, By Service

8.1. Formulation Development Outsourcing Market, by Service, 2023-2032

8.1.1. Preformulation

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Formulation Development

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Formulation Development Outsourcing Market, By Formulation

9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032

9.1.1. Topical

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oral

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Injectable

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area 

10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Infectious Disease

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Respiratory

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Cardiovascular

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Neurology

10.1.5.1. Market Revenue and Forecast (2020-2032)

10.1.6. Hematology

10.1.6.1. Market Revenue and Forecast (2020-2032)

10.1.7. Dermatology

10.1.7.1. Market Revenue and Forecast (2020-2032)

10.1.8. Others

10.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Formulation Development Outsourcing Market, By End-User 

11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032

11.1.1. Pharmaceutical Industries

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Research and Academic Institutions

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 13. Company Profiles

13.1. SGS S.A.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eurofins Scientific SE

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Element

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Labcorp

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific, Inc. (Patheon)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Intertek Group plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Recipharm

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lonza

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Charles River Laboratories International, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Catalent Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: [email protected]

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com